Heptanoic Acid → 4-[5-(4-Heptanoyl-piperazin-1-ylmethyl)-imidazol-1-ylmethyl]-benzonitrile
反応式
[C:1]([C:3]1[CH:21]=[CH:20][C:6]([CH2:7][N:8]2[CH2:13][CH2:12][NH:11][CH2:10][CH:9]2[CH2:14]C2NC=NC=2)=[CH:5][CH:4]=1)#[N:2].[C:22]([OH:30])(=O)[CH2:23][CH2:24][CH2:25][CH2:26][CH2:27][CH3:28].O[N:32]1C2C=CC=CC=2N=N1.[CH2:41]([N:43]([CH2:46]C)CC)[CH3:42].Cl.CN(C)CCCN=C=NCC>CN(C)C=O.C(OCC)(=O)C>[C:22]([N:43]1[CH2:46][CH2:12][N:11]([CH2:10][C:9]2[N:8]([CH2:7][C:6]3[CH:5]=[CH:4][C:3]([C:1]#[N:2])=[CH:21][CH:20]=3)[CH:13]=[N:32][CH:14]=2)[CH2:42][CH2:41]1)(=[O:30])[CH2:23][CH2:24][CH2:25][CH2:26][CH2:27][CH3:28]参加物
反応物 5
生成物 1
試薬・触媒・溶媒 2
実験手順
To a solution of 1-(4′-Cyanobenzyl)imidazol-5-ylmethyl piperazine, prepared as described in Example 1 (65 mg, 0.18 mmol), in 0.5 mL of dimethylformamide at room temperature was added heptanoic acid (0.028 mL, 0.2 mmol), 1-hydroxybenzotriazole (30 mg, 0.22 mmol), triethylamine (0.10 mL, 0.72 mmol), and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (42 mg, 0.22 mmol). After sti!ting overnight, the solution was diluted with ethyl acetate and washed with saturated sodium bicarbonate solution and brine, dried with sodium sulfate, filtered, and concentrated in vacuo. Purification by preparative HPLC was followed by conversion to the bis-hydrochloride salt by exposure of a dichloromethane solution of the product to excess ethereal HCl. Concentration in vacuo provided the titled product as a white powder (23 mg). MS: found: 394 (M+H+)
後処理
- washwashed with saturated sodium bicarbonate solution and brine
- dry with materialdried with sodium sulfate
- filtrationfiltered
- concentrationconcentrated in vacuo
- customPurification by preparative HPLC
- concentrationConcentration in vacuo
出典と根拠
- ORDレコード
- ord-5aa75ee985764e388cc94752066ba9ca
- 出典データセット
- uspto-grants-2002_03
- 特許番号
- US06355643B1
反応ノート
読み込み中…